Xconomy -- Palo Alto, CA-based CardioDx, which developes genomic tests assessing patients’ risk of developing cardiovascular disease, has raised $40 million in a round of equity-based financing, according to a regulatory filing. New investor Longitude Capital led the Series E round, according to a report in Dow Jones VentureWire. CardioDx’s existing investors include Kleiner Perkins Caufield & Byers, TPG Biotech, MDV, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group, and GE Capital.
